Real-world evidence in patient-reported outcomes (PROs) of metastatic castrate-resistant prostate cancer (mCRPC) patients treated with abiraterone acetate + prednisone (AA+P) across Canada: Final results of COSMiC

title = "Real-world evidence in patient-reported outcomes (PROs) of metastatic castrate-resistant prostate cancer (mCRPC) patients treated with abiraterone acetate + prednisone (AA+P) across Canada: Final results of COSMiC",

author = "Rendon, {Ricardo A.}",

note = "Publisher Copyright: {\textcopyright} 2020 Canadian Urological Association",

year = "2020",

month = jun,

doi = "10.5489/CUAJ.6388",

language = "English",

volume = "14",

journal = "Journal of the Canadian Urological Association",

issn = "1911-6470",

publisher = "Canadian Medical Association",

number = "12",

}

TY - JOUR

T1 - Real-world evidence in patient-reported outcomes (PROs) of metastatic castrate-resistant prostate cancer (mCRPC) patients treated with abiraterone acetate + prednisone (AA+P) across Canada

T2 - Final results of COSMiC

AU - Rendon, Ricardo A.

PY - 2020/6

Y1 - 2020/6

UR - http://www.scopus.com/inward/record.url?scp=85090450609&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85090450609&partnerID=8YFLogxK

U2 - 10.5489/CUAJ.6388

DO - 10.5489/CUAJ.6388

M3 - Article

AN - SCOPUS:85090450609

SN - 1911-6470

VL - 14

JO - Journal of the Canadian Urological Association

JF - Journal of the Canadian Urological Association

IS - 12

ER -

Real-world evidence in patient-reported outcomes (PROs) of metastatic castrate-resistant prostate cancer (mCRPC) patients treated with abiraterone acetate + prednisone (AA+P) across Canada: Final results of COSMiC

!!!ASJC Scopus Subject Areas

联合国可持续发展目标

访问文件

其它文件与链接

指纹

引用此